{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:21:47Z","timestamp":1793323307669,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.nefroe.2025.01.010","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:46:08Z","timestamp":1740041168000},"page":"116-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Etelcalcetide: What we know eight years since its approval"],"prefix":"10.1016","volume":"45","author":[{"given":"Pedro","family":"Freitas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2025.01.010_bib0260","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3892\/etm.2016.3438","article-title":"Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease","volume":"12","author":"Wei","year":"2016","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0265","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.ki.5002287","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics","volume":"74","author":"Goodman","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0270","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3122\/jabfm.2009.05.090026","article-title":"Secondary hyperparathyroidism: pathophysiology and treatment","volume":"22","author":"Saliba","year":"2009","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0275","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0280","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.0894-0959.2004.17308.x","article-title":"The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease","volume":"17","author":"Goodman","year":"2004","journal-title":"Semin Dial"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0285","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0290","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10408360590886606","article-title":"The calcium-sensing receptor in normal physiology and pathophysiology: a review","volume":"42","author":"Tfelt-Hansen","year":"2005","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41574-018-0115-0","article-title":"The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases","volume":"15","author":"Hannan","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0310","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.ajkd.2021.05.020","article-title":"Etelcalcetide utilization dosing titration, and chronic kidney disease-mineral and bone disease (CKD-MBD) marker responses in US hemodialysis patients","volume":"79","author":"Karaboyas","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0315","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ckj\/sfx125","article-title":"Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes","volume":"11","author":"Pereira","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0320","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11154-021-09694-6","article-title":"The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies","volume":"23","author":"Chandran","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0325","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/sdi.12413","article-title":"Cinacalcet and clinical outcomes in dialysis","volume":"28","author":"Komaba","year":"2015","journal-title":"Semin Dial"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0330","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000350213","article-title":"Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients","volume":"37","author":"Kilpatrick","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0335","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12882-015-0174-6","article-title":"Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective new-user cohort design","volume":"16","author":"Reams","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0340","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/sdi.12734","article-title":"Treatment of secondary hyperparathyroidism: how do cinacalcet and etelcalcetide differ?","volume":"31","author":"Eidman","year":"2018","journal-title":"Semin Dial"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0345","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/jcm8071066","article-title":"Etelcalcetide in patients on hemodialysis with severe secondary hyperparathyroidism multicenter study in \u201creal life\u201d","volume":"8","author":"Russo","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0350","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0355","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0360","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/jcph.1090","article-title":"Clinical pharmacokinetics and pharmacodynamics of etelcalcetide, a novel calcimimetic for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis","volume":"58","author":"Wu","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0365","doi-asserted-by":"crossref","first-page":"e0213774","DOI":"10.1371\/journal.pone.0213774","article-title":"An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism","volume":"14","author":"Block","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0370","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","article-title":"Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis","volume":"76","author":"Palmer","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0375","first-page":"294","article-title":"Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study","volume":"50","author":"Dudar","year":"2022","journal-title":"Pol Merkur Lekarski"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0380","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nefroe.2022.11.014","article-title":"Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet","volume":"43","author":"Pereira","year":"2023","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0385","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s11255-023-03505-4","article-title":"Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study","volume":"55","author":"Morosetti","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0390","doi-asserted-by":"crossref","first-page":"100475","DOI":"10.1016\/j.xkme.2022.100475","article-title":"Etelcalcetide versus cinacalcet in hemodialysis patients in the United States: a facility calcimimetic approach to assess real-world effectiveness","volume":"4","author":"Karaboyas","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0395","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/ndt\/gfz039","article-title":"One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism","volume":"35","author":"Bushinsky","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0400","first-page":"1723","volume":"32","author":"Fukagawa","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0405","article-title":"Real-world experience of using etelcalcetide for secondary hyperparathyroidism in community-based hemodialysis centers in Singapore","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0410","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1038\/s41598-020-61459-4","article-title":"Hidden hypocalcemia as a risk factor for cardiovascular events and all-cause mortality among patients undergoing incident hemodialysis","volume":"10","author":"Yamaguchi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0415","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2147\/DDDT.S134103","article-title":"Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy","volume":"12","author":"Friedl","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0420","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1161\/CIRCRESAHA.120.318556","article-title":"Randomized trial of etelcalcetide for cardiac hypertrophy in hemodialysis","volume":"128","author":"D\u00f6rr","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0425","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1159\/000533899","article-title":"Etelcalcetide inhibits the progression of left atrial volume index compared to alfacalcidol in hemodialysis patients","volume":"13","author":"D\u00f6rr","year":"2023","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0430","doi-asserted-by":"crossref","first-page":"e9748","DOI":"10.1097\/MD.0000000000009748","article-title":"Prognostic impact of left ventricular mass change in patients with ST-elevation myocardial infarction","volume":"97","author":"Park","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0435","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1681\/ASN.V12122759","article-title":"Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study","volume":"12","author":"London","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0440","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0445","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","article-title":"High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0450","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","article-title":"FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment","volume":"25","author":"Seiler","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0455","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0460","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0465","doi-asserted-by":"crossref","first-page":"F891","DOI":"10.1152\/ajprenal.00163.2014","article-title":"A current understanding of vascular calcification in CKD","volume":"307","author":"Paloian","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0470","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1681\/ASN.2011121191","article-title":"Mechanistic insights into vascular calcification in CKD","volume":"24","author":"Shroff","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0475","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00223-017-0319-7","article-title":"Etelcalcetide, a novel calcimimetic prevents vascular calcification in a rat model of renal insufficiency with secondary hyperparathyroidism","volume":"101","author":"Yu","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0480","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/nu15010167","article-title":"Bone disease in chronic kidney disease and kidney transplant","volume":"15","author":"Bellorin-Font","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0485","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cca.2020.05.023","article-title":"The bone-vessel axis in chronic kidney disease: an update on biochemical players and its future role in laboratory medicine","volume":"508","author":"Pereira","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0490","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bone.2012.09.016","article-title":"Effects of PTH on osteocyte function","volume":"54","author":"Bellido","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0495","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2215\/CJN.0000000000000254","article-title":"Changes in bone quality after treatment with etelcalcetide","volume":"18","author":"Khairallah","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0500","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bone.2017.08.026","article-title":"Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism","volume":"105","author":"Li","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0505","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.010_bib0510","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2215\/CJN.16601020","article-title":"Comparative effects of etelcalcetide and maxacalcitol on serum calcification propensity in secondary hyperparathyroidism","volume":"16","author":"Shoji","year":"2021","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425000161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425000161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:46:25Z","timestamp":1740041185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251425000161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2013251425000161"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.01.010","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etelcalcetide: What we know eight years since its approval","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}